Next Article in Journal
Shortened Tracer Uptake Time in GA-68-DOTATOC-PET of Meningiomas Does Not Impair Diagnostic Accuracy and PET Volume Definition
Next Article in Special Issue
Usefulness of 18f-FDG PET-CT in Staging, Restaging, and Response Assessment in Pediatric Rhabdomyosarcoma
Previous Article in Journal
A Light-Sheet-Based Imaging Spectrometer to Characterize Acridine Orange Fluorescence within Leukocytes
Previous Article in Special Issue
Early Interim Chemotherapy Response Evaluation by F-18 FDG PET/CT in Diffuse Large B Cell Lymphoma
Review

The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future

1
Nuclear Medicine Unit, Department of Medical Sciences, University of Turin, 10126 Turin, Italy
2
Department of Nuclear Medicine, University Hospital Zurich, University of Zurich, 8091 Zurich, Switzerland
3
Department of Endocrinology, University Hospital of Brest, 29200 Brest, France
4
Department of Nuclear Medicine, S.S. Biagio e Antonio e C. Arrigo Hospital, 15121 Alessandria, Italy
5
Department of Nuclear Medicine, AO Ordine Mauriziano di Torino, 10128 Turin, Italy
6
Pathology Unit, City of Health and Science University Hospital, 10126 Turin, Italy
7
Department of Oncology, University of Turin at Molinette Hospital, 10126 Turin, Italy
8
Department of Endocrinology, A. O. U. Città della Salute della Scienza of Turin, 10126 Turin, Italy
9
Oncological Endocrinology, Department of Medical Sciences, University of Turin, 10126 Turin, Italy
*
Author to whom correspondence should be addressed.
Diagnostics 2020, 10(12), 1083; https://doi.org/10.3390/diagnostics10121083
Received: 16 November 2020 / Revised: 9 December 2020 / Accepted: 9 December 2020 / Published: 12 December 2020
(This article belongs to the Special Issue Positron Emission Tomography (PET) Imaging for Therapy Monitoring)
The NETTER-1 study has proven peptide receptor radionuclide therapy (PRRT) to be one of the most effective therapeutic options for metastatic neuroendocrine tumors (NETs), improving progression-free survival and overall survival. However, PRRT response assessment is challenging and no consensus on methods and timing has yet been reached among experts in the field. This issue is owed to the suboptimal sensitivity and specificity of clinical biomarkers, limitations of morphological response criteria in slowly growing tumors and necrotic changes after therapy, a lack of standardized parameters and timing of functional imaging and the heterogeneity of PRRT protocols in the literature. The aim of this article is to review the most relevant current approaches for PRRT efficacy prediction and response assessment criteria in order to provide an overview of suitable tools for safe and efficacious PRRT. View Full-Text
Keywords: peptide receptor radionuclide therapy; PRRT; 68Ga-labeled somatostatin analogue; 18F-FDG; response assessment; RECIST; SWOG; WHO; neuroendocrine tumors; NET peptide receptor radionuclide therapy; PRRT; 68Ga-labeled somatostatin analogue; 18F-FDG; response assessment; RECIST; SWOG; WHO; neuroendocrine tumors; NET
Show Figures

Figure 1

MDPI and ACS Style

Liberini, V.; Huellner, M.W.; Grimaldi, S.; Finessi, M.; Thuillier, P.; Muni, A.; Pellerito, R.E.; Papotti, M.G.; Piovesan, A.; Arvat, E.; Deandreis, D. The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future. Diagnostics 2020, 10, 1083. https://doi.org/10.3390/diagnostics10121083

AMA Style

Liberini V, Huellner MW, Grimaldi S, Finessi M, Thuillier P, Muni A, Pellerito RE, Papotti MG, Piovesan A, Arvat E, Deandreis D. The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future. Diagnostics. 2020; 10(12):1083. https://doi.org/10.3390/diagnostics10121083

Chicago/Turabian Style

Liberini, Virginia, Martin W. Huellner, Serena Grimaldi, Monica Finessi, Philippe Thuillier, Alfredo Muni, Riccardo E. Pellerito, Mauro G. Papotti, Alessandro Piovesan, Emanuela Arvat, and Désirée Deandreis. 2020. "The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future" Diagnostics 10, no. 12: 1083. https://doi.org/10.3390/diagnostics10121083

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop